Advanced Modalities: NPWT, HBOT, CTPs & Biophysical Therapies
Key Takeaways
- Negative pressure wound therapy (NPWT) applies controlled subatmospheric pressure to promote granulation, manage exudate, and reduce edema; CWCA associates commonly assist with application/removal under protocol.
- Hyperbaric oxygen therapy (HBOT) delivers 100% oxygen at elevated atmospheric pressure to raise tissue oxygen tension and is indicated for selected hypoxic or infected wounds after specialist evaluation.
- Cellular and/or tissue products (CTPs) and skin substitutes provide biologic scaffolds or living cells for stalled chronic wounds and are ordered/applied under advanced clinician direction.
- Biophysical technologies on the CWCA outline include electrical stimulation and therapeutic ultrasound as adjunctive modalities for selected chronic wounds.
- Surgical closure and tissue transfer (grafts/flaps) require assist-level knowledge of indications, graft protection, and escalation rather than independent operative decision-making by the CWCA.
Advanced Modalities: NPWT, HBOT, CTPs & Biophysical Therapies
Official Patient Management content includes advanced interventions that CWCAs must recognize, prepare for, monitor, and escalate—even when they do not independently prescribe or initiate them. High-yield modalities include negative pressure wound therapy (NPWT), hyperbaric oxygen therapy (HBOT), cellular and/or tissue products (CTPs), biophysical technologies (electrical stimulation and ultrasound), and surgical closure or tissue transfer.
Negative Pressure Wound Therapy (NPWT)
NPWT delivers controlled subatmospheric pressure through a sealed foam or gauze interface connected to a pump. Typical therapeutic set-points in standard continuous therapy are often around −80 to −125 mmHg, though ordered settings vary by device, tissue type, and clinician preference.
| Clinical Effect | Mechanism Relevant to Healing |
|---|---|
| Exudate management | Continuous removal of fluid reduces maceration and bioburden burden |
| Edema reduction | Interstitial fluid removal improves local perfusion |
| Macrostrain / microstrain | Tissue deformation stimulates granulation and angiogenesis |
| Occlusive protection | Sealed system protects from environmental contamination |
Typical indications
- Deep, highly exudative wounds with adequate perfusion
- Dehisced surgical wounds after infection control
- Selected traumatic wounds and flaps/grafts (per protocol)
- Stage 3–4 pressure injuries after debridement of nonviable tissue (when ordered)
Common contraindications / stop rules
- Untreated osteomyelitis or uncontrolled infection
- Malignancy in the wound
- Exposed unprotected organs, major vessels, or anastomoses (device-specific rules)
- Unexplored fistulas
- Necrotic eschar without debridement pathway
- Fragile periwound skin unable to maintain an airtight seal
CWCA role
- Assist with application and removal under the plan of care
- Verify foam does not overlap intact skin; protect periwound with barrier film or drape
- Monitor for seal integrity, canister fill, bleeding, increasing pain, and signs of infection
- Escalate immediately for bright-red bleeding into the canister, fever, or sudden loss of seal with uncontrolled drainage
[ Clean / debride as ordered ] → [ Interface foam/gauze ] → [ Occlusive drape ]
→ [ Connect tubing ] → [ Initiate ordered pressure ] → [ Monitor seal & output ]
Hyperbaric Oxygen Therapy (HBOT)
HBOT administers 100% oxygen at pressures greater than 1 atmosphere absolute (commonly 2.0–2.4 ATA for wound indications) inside a monoplace or multiplace chamber. Elevated plasma-dissolved oxygen increases tissue oxygen tension, supports leukocyte oxidative killing, and may stimulate angiogenesis in selected hypoxic wounds.
Wound-related indications commonly tested conceptually
- Selected diabetic foot ulcers with demonstrated tissue hypoxia (often using TcPO2 assessment)
- Chronic refractory osteomyelitis
- Compromised grafts/flaps
- Delayed radiation injury (soft tissue or osteoradionecrosis)
- Clostridial myonecrosis / selected necrotizing infections (as adjunct)
CWCA priorities
- Recognize HBOT as an adjunct, not a substitute for off-loading, infection control, perfusion, and moisture balance
- Screen for referral red flags: non-healing hypoxic wounds despite optimized standard care
- Know major contraindications at a recognition level (e.g., untreated pneumothorax is an absolute contraindication; caution with certain chemotherapies and uncontrolled seizure disorders)
- Educate patients on ear equalization, fire safety, and session expectations
Cellular and/or Tissue Products (CTPs) and Skin Substitutes
CTPs (also called cellular and tissue-based products or skin substitutes) include acellular matrices and cellular constructs used on stalled chronic wounds after optimization of the wound bed.
| Product Class | Conceptual Role | CWCA Focus |
|---|---|---|
| Acellular dermal/matrix products | Scaffold for host cell migration | Protect graft, maintain moist environment, avoid shear |
| Cellular constructs | Living cells + matrix components | Strict handling/storage rules; immobilization as ordered |
| Bioengineered skin substitutes | Temporary coverage / biologic stimulus | Document measurements supporting medical necessity |
CTP application is ordered and performed under advanced clinician authority. The CWCA contributes by preparing the wound bed (cleansing, non-selective dressing changes), protecting the product after placement, monitoring for infection or dislodgement, and documenting objective measurements that support medical necessity and follow-up.
Biophysical Technologies: Electrical Stimulation and Ultrasound
The official outline specifically lists biophysical technologies:
- Electrical stimulation (E-stim) — monophasic or pulsed current protocols used as adjuncts to stimulate healing in selected chronic wounds when standard care is insufficient. Exact waveforms and polarity are ordered by qualified clinicians.
- Therapeutic ultrasound — low-frequency or non-contact low-frequency ultrasound may assist with debridement, bioburden reduction, or perfusion support depending on modality.
CWCA exam expectations emphasize:
- Knowing these are adjunctive Patient Management options
- Identifying candidates: stalled chronic wounds with adequate perfusion and controlled infection
- Recognizing when to escalate for specialist-directed biophysical therapy rather than endlessly rotating passive dressings
Surgical Closure and Tissue Transfer (Assist-Level Knowledge)
Domain 3 also includes surgical closure or tissue transfer. Associates should understand:
- Primary closure after clean sharp wound edges and adequate perfusion
- Skin grafts (split-thickness vs full-thickness): require immobilization, shear protection, and monitoring for seroma/hematoma/infection
- Flaps / tissue transfer: move vascularized tissue; monitor for color, temperature, capillary refill, and congestion
CWCA actions after graft/flap procedures typically include protective dressings as ordered, limb elevation when indicated, activity restrictions, and immediate escalation for dusky color, coolness, uncontrolled bleeding, or purulent drainage.
Case Review Mindset
Patient Management also expects case review skills: synthesizing labs, imaging, perfusion data, nutrition markers, and healing trajectory to identify outliers and escalate prognosis concerns. A practical CWCA checklist:
- Is perfusion adequate (pulses, ABI/TBI, TcPO2 when available)?
- Is infection/biofilm controlled?
- Is off-loading/compression appropriate and tolerated?
- Is nutrition optimized (protein, calories, micronutrients)?
- Has area reduction met expected milestones (commonly ~30–50% by 4 weeks)?
- If not, escalate for modality change (NPWT, CTP, HBOT, surgical options) rather than passive continuation.
Which finding is an immediate reason to stop NPWT and escalate care?
Which statement best reflects the CWCA role with cellular and/or tissue products (CTPs)?
Which pair of biophysical technologies is explicitly included in the official CWCA Patient Management outline?